HSD3B7 and nonpapillary renal cell carcinoma: The recently reported role of HSD3B7 in ccRCC and the established supplementation of cholic acid treatment for HSD3B7 deficiencies suggests that the activity of HSD3B7 could be manipulated for therapeutic purposes.